Literature DB >> 15546383

Interferons, interferon-like cytokines, and their receptors.

Sidney Pestka1, Christopher D Krause, Mark R Walter.   

Abstract

Recombinant interferon-alpha (IFN-alpha) was approved by regulatory agencies in many countries in 1986. As the first biotherapeutic approved, IFN-alpha paved the way for the development of many other cytokines and growth factors. Nevertheless, understanding the functions of the multitude of human IFNs and IFN-like cytokines has just touched the surface. This review summarizes the history of the purification of human IFNs and the key aspects of our current state of knowledge of human IFN genes, proteins, and receptors. All the known IFNs and IFN-like cytokines are described [IFN-alpha, IFN-beta, IFN-epsilon, IFN-kappa, IFN-omega, IFN-delta, IFN-tau, IFN-gamma, limitin, interleukin-28A (IL-28A), IL-28B, and IL-29] as well as their receptors and signal transduction pathways. The biological activities and clinical applications of the proteins are discussed. An extensive section on the evolution of these molecules provides some new insights into the development of these proteins as major elements of innate immunity. The overall structure of the IFNs is put into perspective in relation to their receptors and functions.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15546383     DOI: 10.1111/j.0105-2896.2004.00204.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  587 in total

Review 1.  Biological therapy and the immune system in patients with chronic myeloid leukemia.

Authors:  Peter Rohon
Journal:  Int J Hematol       Date:  2012-06-04       Impact factor: 2.490

2.  Generation of Trypanosoma cruzi-specific CD8+ T-cell immunity is unaffected by the absence of type I interferon signaling.

Authors:  Diana L Martin; Kaja Murali-Krishna; Rick L Tarleton
Journal:  Infect Immun       Date:  2010-05-10       Impact factor: 3.441

3.  Serum TNF-α, B2M and sIL-2R levels are biological correlates of outcome in adjuvant IFN-α2b treatment of patients with melanoma.

Authors:  Maja A Hofmann; Felix Kiecker; Ingeborg Küchler; Christian Kors; Uwe Trefzer
Journal:  J Cancer Res Clin Oncol       Date:  2010-05-09       Impact factor: 4.553

4.  Induction of IFN-α subtypes and their antiviral activity in mumps virus infection.

Authors:  Maja Markušić; Maja Šantak; Tanja Košutić-Gulija; Mladen Jergović; Renata Jug; Dubravko Forčić
Journal:  Viral Immunol       Date:  2014-12       Impact factor: 2.257

5.  Type I interferon signals control Theiler's virus infection site, cellular infiltration and T cell stimulation in the CNS.

Authors:  Young-Hee Jin; Wanqiu Hou; Seung Jae Kim; Alyson C Fuller; Bongsu Kang; Gwen Goings; Stephen D Miller; Byung S Kim
Journal:  J Neuroimmunol       Date:  2010-06-09       Impact factor: 3.478

6.  Type III IFNs in pteropid bats: differential expression patterns provide evidence for distinct roles in antiviral immunity.

Authors:  Peng Zhou; Chris Cowled; Shawn Todd; Gary Crameri; Elena R Virtue; Glenn A Marsh; Reuben Klein; Zhengli Shi; Lin-Fa Wang; Michelle L Baker
Journal:  J Immunol       Date:  2011-01-28       Impact factor: 5.422

7.  Excess type I interferon signaling in the mouse seminiferous tubules leads to germ cell loss and sterility.

Authors:  Anne-Pascale Satie; Severine Mazaud-Guittot; Isabelle Seif; Dominique Mahé; Zhiguo He; Guilhem Jouve; Bernard Jégou; Nathalie Dejucq-Rainsford
Journal:  J Biol Chem       Date:  2011-04-22       Impact factor: 5.157

8.  Localization of type I interferon receptor limits interferon-induced TLR3 in epithelial cells.

Authors:  Jonathan M Ciencewicki; Luisa E Brighton; Ilona Jaspers
Journal:  J Interferon Cytokine Res       Date:  2009-05       Impact factor: 2.607

9.  Short-Term Pegylated Interferon α2a Treatment Does Not Significantly Reduce the Viral Reservoir of Simian Immunodeficiency Virus-Infected, Antiretroviral Therapy-Treated Rhesus Macaques.

Authors:  David Palesch; Steven E Bosinger; Maud Mavigner; James M Billingsley; Cameron Mattingly; Diane G Carnathan; Mirko Paiardini; Ann Chahroudi; Thomas H Vanderford; Guido Silvestri
Journal:  J Virol       Date:  2018-06-29       Impact factor: 5.103

10.  Genetic manipulation of the ApoF/Stat2 locus supports an important role for type I interferon signaling in atherosclerosis.

Authors:  William R Lagor; David W Fields; Robert C Bauer; Alison Crawford; Michael C Abt; David Artis; E John Wherry; Daniel J Rader
Journal:  Atherosclerosis       Date:  2014-01-10       Impact factor: 5.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.